You are here

Home » Content

IL-2 ETKİSİ İLE AKTİF HALE GETİRİLEN MODİFİYE MLC TESTİNDE İMMUNOSUPRESAN İLAÇLARIN ETKİSİ

Journal Name:

  • İstanbul Tıp Fakültesi Dergisi

Publication Year:

  • 2001

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Effect of İmmıııısııpressive drııgs in Wodified WLC with activated IL-2. SMLC is a method which is used in choosing an adequate donor for allogeneic bone marrow transplantation (BMT) patients by detecting human leukocyte antigen (HLA)-D antigens. Besides, with this method HLA-DP and minör histocompatibility and eventually graft versus host disease (GVHD) may not be detected. Proliferative responses if exist between donor and recipient and to ameliorate BMT outcomes standart mixed lymphocyte culture (sMLC) can be modified. IL-2 was added in 25 donor-recipient combinations undergoing BMT and sMLC and we tried to detect the difference due to antigens. In 19 patients, modified MLC (mMLC) test results are found be increased. This increase is suggested to result from the differences mentioned above. Susceptibility of individuals to different immunosupressive agent varies. Susceptibility and re-sistance is important in the acceptance and rejection of the graft for this reason, this agent are added to mMLC and compare their antiproliferative effect are compared. 12 out of 26 tests show susceptibility to MeP where is 13 tests to Cyc-A. Only one test show equal resistance to Mep and Cyc-A.
Bookmark/Search this post with
Abstract (Original Language): 
Standart mixed lymphocyte culture (Standart karışık lenfosit kültürü-sMLC) allogeneik kemik iliği transplantasyonu (KİT) yapılacak hastalara uygun vericinin seçilmesinde, özellikle human leukocyte antigen (HLA)-D grubu antijenlerini saptamak için kullanılan bir yöntemdir. Bununla birlikte sMLC ile HLA-DP ve minör histokompatibilite antijenlerinin uyumsuzluğu ve bunun sonucunda oluşan graft versus host hastalığı (GVHH) belirlenemeyebilir. Alıcı ve do-nör arasında, eğer varsa saptanamayan proliferatif cevapları saptamak ve KİT'da başarıyı arttırmak amacıyla sMLC modifiye edilebilir. Bu nedenle KİT'na hazırlanan ve sMLC sonucu negatif olan, 25 bireyin farklı yönlerdeki 26 alıcı-verici hücre kombinasyonuna aynı zamanda interlökin-2 (IL-2) ilave ederek modifiye ettiğimiz MLC (mMLC) ile de bu antijenlere bağlı farklılığı saptamayı amaçladık. 19 mMLC testinde SI değerlerindeki artışında bu farklılıktan kaynaklanabileceğini düşündük. Immunsupresiflere karşı oluşan duyarlılık ve direnç bireyden bireye değişiklik göstermektedir. Bu da graftın kabul veya reddedilmesinde rol oynamaktadır. Bu nedenle mMLC testine, nakil sonrası kullanılan ajanlardan çyclosporine-A (Cyc-A) ve methylprednisolone (MeP) ekleyerek, bu ajanların antiproliferatif etkilerini karşılaştırdık. Sonuçta 26 testten 12'sinin MeP'e, 13'ünün Cyc-A'ya daha duyarlı olduğunu gördük. Bir testte ise MeP ve Cyc-A'ya karşı olan duyarlılığın eşit olduğunu saptadık.
FULL TEXT (PDF): 
PDF icon arastirmax-il-2-etkisi-ile-aktif-hale-getirilen-modifiye-mlc-testinde-immunosupresan-ilaclarin-etkisi.pdf
  • 4
243-248
  • Turkish

REFERENCES

References: 

1. Amal B, Chaim B, Aman N, Shimon S, Benny L, Izhak C, Eli K: Prediction by a modified mixed leukocyte reac-tion assay of graft-versus host disease and graft rejection after allogeneic bone marrovv transplantation, Transplantation 57: 1474(1994).
2. Degiannis D, Czannecki M, Hornung N, Raskova J, Ras-ka K: Mixed lymphocyte ıeaction-induced release of so-luble IL-2 receptor, Transplantation 51:518 (1991).
3. Dupond B, Handsen J, Yunis ES: Human Mixed Lymphocyte culture reaction, genetics, specificity and biological implications Adv. Immunology 107 (1976).
4. Gale RP, Bortin MM, Van Bekkunı DV: Risk factors for acut graft-versus host disease, Br J Hematol 67; 397 (1987).
5. Giguere V, Hollenberg SM, Rosenfeld MG, Evans RM: Functional domains of the human ghıcocorticoid receptor, Celi 46: 645 (1986).
6. Goulmy E: Minör histocompatibility antigen in man and their role in transplantation, Transplant Rev 2 (1988).
7. Goulmy E, Gratame JW, Blockland E, Evans FE, von Rood JJ: A minör transplantation antigen detected by MHC restricted cytotoxic T lymphocytes during graft-versus host disease, Nature 302: 159 (1983).
8. Hansen JA, Mickelson E, Beaty PG, Thomas D: Clinical bone marrovv transplantation, donor selection and recipi-ent monitoring, In: NR. Rose, H. Friedman, JL. Fahey, eds. Manual of Clinical Laboratory Immunology, 3rd ed. American Society for Microbiology, Washington DC, 892(1986).
9. Hansen SA, Mickelson EM, Choo SY, et al: Clinical bone marrow transplantation. Donor selection and recipient monitoring In: Rose NR, Dc Mucario EC, Rahey SL, Friedman H, Penn GM eds.: Manual of Clinical Laboratory Immunology American Society Microbiology, 350 (1992).
10. Hollenberg SM, Giguere V, Segui P, Evans RM: Coloca-lization of human glucocorticoid receptor, Celi 49: 39 (1987).
11. Irle C, Beaty PG, Mickelson E, Thomas D, Hansen J: Al-loreactive T celi responses betvveen HLA- identical sib-
lings: Detection of anti-minor histocompatibility T celi clones induced in vivo, Transplantation 40: 329 (1985).
12. Konuk N: Akut Graft Versus Host Hastalığı, Klinik Gelişim 10: 57 (1997).
13. Kuby J: Transplantation Immunology, Immunology, Third edition, 567 (1997).
14. Lim SH, Patton WM, Jobson S, et al: Mixed lymphocyte reactions do not predict severity of graft versus host disease (GVHD) in HLA-DR compatible sibling bone mar-row transplants, J Clin Pathol 41: 1155 (1988).
15. Moreau P, Bignon JD, Milpied N, et al: Genomic HLA-class II typing (DR, DQ, DP) MLR I and GVH disease: retrospective study of 41 allogeneic bone marrow trans-plantations, XVth Annual ASHI Meeting, Human Immunology (Special Issue), Toronto, (1989)
16. Moreau P, Cesborn A: HLA DP and allogeneic bone mar-row transplantation, Bone Marrow Transplant 13: 675 (1994).
17. Odum N, Platz P, Jakobsen BK, et al: HLA-DP and bone marrow transplantation: DP incompatibility and severe acute graft-versus host disease, Tissue Antigen 30: 213 (1987).
18. Pawelec G, Ehninger G, Schmat H, Wernet P: HLA DP matching and graft versus host disease in allogeneic bone marrow transplantation, Transplantation 42: 588 (1986).
19. Peakman M, Vetgani D: Transplantation, Basic and Clinical Immunology. 160(1996).
20. Pollak R, Dumble LJ, Lazda VA, Maddux MS, Stormoen B, Ward M: Utility of in vitro immunoassay guide im-munosupressive therapy, Transplant Proc 23: 1113 (1991).
21. Roitt I, Brostoff S, Male D: Transplantation and Rejection, Cellular and Molecular Immunology Second Cellular and Molecular Immunology, Fourth edition, 26:8 (1996).
22. Stites DS, Terr AL, Parslovv TG: Clinical Transplantation, Basic and Clinical Immunology, 744 (1994).
23. Stites DP, Terr Al, Parslovv TG: Cytokines, Basic and Clinical Immunology, Eighlh edition, 100 (1994).
24. Storb R, Deeg HJ, Pepe M, et al: Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft versus host disease in patients given HLA identical marrow gıafts for leukemia: Long-term folow-up of a controlled trial, Blood 73: 1729 (1989).
25. Susanne G, Danzer H, Kirchner L, Rink: Cytokine inte-ractions in human mixed lymphocyte culture, Transplantation 57: 1638(1994).
26. Zeevi A, Yao G-Z, Venkataramanan R, Dujuesnoy RJ, Todo S, Fung JJ, Starzl TE: Comparative in vitro studies on the immunosupressive effects of purin and pyrimidine synthesis inhibitors, Transplant Proc 25: 781 (1993).

Thank you for copying data from http://www.arastirmax.com